Amgen Inc. announced robust first quarter 2026 financial results, with total revenue of $8.62 billion, surpassing expectations and prompting a raise in full-year revenue guidance to $37.1-$38.5 billion. The company also revealed a $300 million investment in U.S. manufacturing to support future growth, despite facing a significant 37% drop in Enbrel sales and challenges from biosimilars. Amgen remains confident, highlighting 16 products achieving double-digit sales growth as key drivers to offset these setbacks.
“Amgen (AMGN) · is currently shelling out a dividend of · $2.52 per share”
“Amgen is developing MariTide as a · single dose in a convenient · autoinjector device · true”
“Amgen · is · one of the world's leading biotechnology companies”
“Amgen · has · a total investment of nearly $2 billion · over the last year”
“Amgen · announced · an additional $300 million U.S. manufacturing investment”
“Amgen · reported · first quarter 2026 financial results”
“Amgen · is listed on · NASDAQ · with the symbol AMGN”
“AMGN · has a location · Thousand Oaks, CA”
“AMGN · announced a stock dividend of · $2.52 · MAY 15”
“AMGN · beat Q1 earnings by · $5.15 · APR 30”
“AMGN · has collaborated with · AstraZeneca plc · for the development and commercialization of TEZSPIRE”
“AMGN · has a product · Enbrel · for treatment of rheumatoid arthritis”
